GlassScriptPhysician profile
Janet Ann Collins
NPI 1609888692
$5,317.89
in general payments reported to CMS, 2019-2025
27 companies · $845 in 2025
The $845 reported for 2025 was more than what 83% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $232 · 2021: $616 · 2022: $749 · 2023: $970 · 2024: $867 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.79 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $594.83 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $549.61 | 2021-2025 | Caplyta |
| Alkermes, INC. | $427.47 | 2022-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $364.09 | 2019-2025 | Trintellix |
| Tris Pharma INC | $312.43 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $295.34 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $272.35 | 2019-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $270.27 | 2019-2025 | Brintellix, Rexulti |
| Supernus Pharmaceuticals, INC. | $245.18 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $237.20 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $197.37 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $192.32 | 2022-2025 | Auvelity |
| Shire North American Group INC | $145.02 | 2019 | |
| Sunovion Pharmaceuticals INC. | $112.86 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $90.23 | 2022-2024 | Jornay Pm |
| Allergan, INC. | $70.62 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $54.79 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $53.62 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $45.78 | 2022-2024 | Ingrezza |
| Neos Therapeutics, LP | $26.76 | 2019 | |
| Adlon Therapeutics L.P. | $26.15 | 2020 | |
| Arbor Pharmaceuticals, INC. | $23.12 | 2019 | |
| Merck Sharp & Dohme LLC | $19.99 | 2023 | Belsomra |
| Almatica Pharma LLC | $18.06 | 2025 | Loreev Xr |
| Noven Therapeutics, LLC | $17.87 | 2024 | Secuado |
| Vertical Pharmaceuticals, LLC | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.